Fresenius SE KGaA (BATS-CHIXE:FRED) - Stock Price, News & Analysis

FRED Stock Overview

A health care company, provides products and services for chronically ill patients. More details

FRED fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	4/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 60.7% below our estimate of its fair value

Earnings are forecast to grow 39.03% per year

Analysts in good agreement that stock price will rise by 20.5%

Risk Analysis

Has a high level of debt

Fresenius SE & Co. KGaA Competitors

Integrated Diagnostics Holdings

LSE:IDHC

US$225.8m

Smith & Nephew

LSE:SN.

UK£8.6b

Mediclinic International

LSE:MDC

UK£3.7b

ConvaTec Group

LSE:CTEC

UK£4.9b

Price History & Performance

Summary of all time highs, changes and price drops for Fresenius SE KGaA
Historical stock prices
Current Share Price	€33.09
52 Week High	€36.00
52 Week Low	€24.66
Beta	1.04
11 Month Change	-0.90%
3 Month Change	2.75%
1 Year Change	23.61%
33 Year Change	-6.23%
5 Year Change	-33.43%
Change since IPO	27.69%

Recent updates

Shareholder Returns

	FRED	GB Healthcare	GB Market
7D	-3.2%	-3.9%	-0.3%
1Y	23.6%	-24.2%	6.1%

Return vs Industry: FRED exceeded the UK Healthcare industry which returned -23.8% over the past year.

Return vs Market: FRED exceeded the UK Market which returned 5.6% over the past year.

Price Volatility

Is FRED's price volatile compared to industry and market?
FRED volatility
FRED Average Weekly Movement	4.3%
Healthcare Industry Average Movement	6.4%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: FRED has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine FRED's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1912	177,091	Michael Sen	www.fresenius.com

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

Fresenius SE & Co. KGaA Fundamentals Summary

How do Fresenius SE KGaA's earnings and revenue compare to its market cap?
FRED fundamental statistics
Market cap	€18.79b
Earnings (TTM)	-€479.00m
Revenue (TTM)	€22.81b

0.8x

P/S Ratio

-39.2x

P/E Ratio

Is FRED overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FRED income statement (TTM)
Revenue	€22.81b
Cost of Revenue	€17.48b
Gross Profit	€5.33b
Other Expenses	€5.81b
Earnings	-€479.00m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.85
Gross Margin	23.37%
Net Profit Margin	-2.10%
Debt/Equity Ratio	60.9%

How did FRED perform over the long term?

See historical performance and comparison

FRED Stock Overview

Rewards

Risk Analysis

Fresenius SE & Co. KGaA Competitors

LSE:IDHC

US$225.8m

LSE:SN.

UK£8.6b

LSE:MDC

UK£3.7b

LSE:CTEC

UK£4.9b

Price History & Performance

Recent News & Updates

PAI Mid-Market Fund SCSp. managed by PAI Partners completed the acquisition of 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

First quarter 2024 earnings released: EPS: €0.49 (vs €0.61 in 1Q 2023)

PAI Mid-Market Fund SCSp. managed by PAI Partners agreed to acquire 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA (XTRA:FRE).

New major risk - Financial position

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC completed the acquisition of EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE).

Recent updates

PAI Mid-Market Fund SCSp. managed by PAI Partners completed the acquisition of 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

First quarter 2024 earnings released: EPS: €0.49 (vs €0.61 in 1Q 2023)

PAI Mid-Market Fund SCSp. managed by PAI Partners agreed to acquire 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA (XTRA:FRE).

New major risk - Financial position

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC completed the acquisition of EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE).

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC completed the acquisition of EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE).

German Fresenius Reportedly Seeks to Sell Vamed Reha

Fresenius SE & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 14, 2024

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC agreed to acquire EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE) for €500 million.

Third quarter 2023 earnings released: EPS: €0.72 (vs €0.57 in 3Q 2022)

Fresenius SE & Co. KGaA to Report Q2, 2024 Results on Jul 31, 2024

KKR in Talks to Buy Eugin from Fresenius

Fresenius Reportedly Plans to Offload Digital Subsidiary Curalie

New major risk - Financial position

Second quarter 2023 earnings released: EPS: €0.14 (vs €0.68 in 2Q 2022)

Fresenius SE & Co. KGaA to Report Q3, 2023 Results on Nov 02, 2023

Fresenius Se & Co. Kgaa Proposes Dividend for 2022

Upcoming dividend of €0.92 per share at 3.3% yield

Fresenius SE & Co. KGaA to Report Q1, 2023 Results on May 09, 2023

Full year 2022 earnings released: EPS: €2.44 (vs €3.26 in FY 2021)

Fresenius SE & Co. KGaA, Annual General Meeting, May 17, 2023

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

Third quarter 2022 earnings released: EPS: €0.57 (vs €0.74 in 3Q 2021)

Brookfield Reportedly Drops Out of Race to Buy Healius

Fresenius SE Announces Chief Financial Officer Changes

Fresenius SE & Co. KGaA Announces Michael Sen as CEO on October 1, 2022 Succeeding Stephan Sturm

Second quarter 2022 earnings released: EPS: €0.68 (vs €0.84 in 2Q 2021)

Healius Reportedly Launches Day Surgery Sale Process

Fresenius Kabi Introduces Generic Iodixanol Contrast Media Agent

Upcoming dividend of €0.92 per share

First quarter 2022 earnings released: EPS: €0.74 (vs €0.78 in 1Q 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Fresenius SE & Co. KGaA Provides Earnings Guidance for the Year 2022

Third quarter 2021 earnings released: EPS €0.74 (vs €0.77 in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.84 (vs €0.74 in 2Q 2020)

Upcoming dividend of €0.88 per share

First quarter 2021 earnings released: EPS €0.78 (vs €0.82 in 1Q 2020)

Full year 2020 earnings released: EPS €3.06 (vs €3.38 in FY 2019)

New 90-day high: €40.09

Fresenius SE & Co. KGaA to Report Q1, 2021 Results on May 07, 2021

Fresenius SE & Co. KGaA, Annual General Meeting, May 21, 2021

Shareholder Returns

Price Volatility

About the Company

Fresenius SE & Co. KGaA Fundamentals Summary

0.8x

-39.2x

Earnings & Revenue